News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|July 10, 2022

Talking with Amy Paller, MD, about the Society for Pediatric Dermatology Meeting

Author(s)Lois Levine, MA

At the SPD 2022 47th Annual Meeting, we talk with Amy Paller, MD, about her panel session on Indications of AD, Alopecia, and Vitiligo

Amy Paller, MD, MS, is the Walter J. Hamlin professor, chair of Dermatology and professor of Pediatrics at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. Here she discusses exciting takeaways from her panel, "Indications of AD, Alopecia and Vitiligo (Practical Pearls)" at this year's Society for Pediatric Dermatology Meeting.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

ByDruhan Howell, MD

November 25th 2025

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults | Image credit: Contemporary Pediatrics

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

ByJoshua Fitch, Senior Editor

November 25th 2025

FDA approves first gene replacement therapy (Itvisma) for patients 2 years and older with spinal muscular atrophy | Image credit: Contemporary Pediatrics

FDA approves first gene replacement therapy (Itvisma) for patients 2 years and older with spinal muscular atrophy

ByMorgan Ebert, Managing Editor

November 25th 2025

Jonathan Flyer, MD, highlights the LEAD initiative to increase pediatric lipid screenings

Jonathan Flyer, MD, highlights the LEAD initiative to increase pediatric lipid screenings

ByJonathan N. Flyer, MD

November 24th 2025

Can you diagnose this corneal lesion in an 8-year-old girl?

Can you diagnose this corneal lesion in an 8-year-old girl?

ByJenna Scanlon, DO,Melissa Mondello, MD,Jennifer Haile, MD

November 24th 2025

Latest CME

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA approves first gene replacement therapy (Itvisma) for patients 2 years and older with spinal muscular atrophy

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

Ruxolitinib Efficacy and Safety in Pediatric AD

Jonathan Flyer, MD, highlights the LEAD initiative to increase pediatric lipid screenings

© 2025 MJH Life Sciences^®

All rights reserved.